The Center
Multiple Sclerosis Center Dresden
Patient Information
Contact MSC
Physicians & Nurses
Study Team
Neuropsychology
Mobility Center
The Mobility Center
Walking Assessment
Jump Assessment
DIERS
EMIQ
Projects
Neuroimmunological Laboratory
The NIL
Neurofilament light chain
Autonomic & Neuroendocrinological Functional Laboratory
The ANF
ANF Assessment
MS Living Lab
Management & Science
Team Management & Science
Projects
eHealth & Analytics
MSDS 3D
MSDS Clinic & Practice
MS-HRS
MTRS
Multiple Sclerosis Management
Aktuelles
Neuigkeiten
Publikationen
Veranstaltungen
Adventssymposium
Multiple Sklerose 360°
Welt-MS-Tag 2021
Doktorarbeiten
Jobs
Kontakt
Podcasts & Newsletter
Newsletter
Patienten-Podcast
Ärzte-Podcast
Studien
Interventionelle Studien
B-SHUTTLE
Nicht-interventionelle Studien
MS PATHS
Konectom
Sprachanalyse
English (UK)
Deutsch
English (UK)
Claims-based algorithm to estimate the Expanded Disability Status Scale for multiple sclerosis in a German health insurance fund: a validation study using patient medical records
MASC
Jahr
Publikationsjahr
2023
Autoren
Autorenliste der Publikation
Muros-Le Rouzic E, Ghiani M, Zhuleku E, Dillenseger A, Maywald U, Wilke T, Ziemssen T, Craveiro L.
Verlag
Publisher-Information
Front Neurol. 2023 Dec 7;14:1253557.
Link
Zur Publikation (externer Server)
https://doi.org/10.3389/fneur.2023.1253557
Tags
Forschungsthemen
Multiple Sklerose
Management & Science
Gesundheitsökonomie
MSZ
MASC
2023
Health economics
Escalating to medium- versus high-efficacy disease modifying therapy after low-efficacy treatment in relapsing remitting multiple sclerosis
MS Treatments
Jahr
2024
Data on Ocrelizumab Treatment Collected by MS Patients in Germany Using Brisa App
MS Treatments
Jahr
2024
Evaluation der langfristigen klinischen und ökonomischen Auswirkungen einer Behandlung mit Ofatumumab gegenüber Dimethylfumarat und Glatirameracetat bei Patienten mit schubförmiger Multipler Sklerose aus gesellschaftlicher Sicht in Deutschland
MS Treatments
Jahr
2022
Comparison of time to clinically meaningful improvement in quality of life in neurological disorders in patients treated with natalizumab versus ocrelizumab
MS Treatments
Jahr
2024
Sensitive Identification of Asymmetries and Neuromuscular Deficits in Lower Limb Function in Early Multiple Sclerosis
Mobility
Jahr
2024